There have been important developments in recent weeks on the 340B drug pricing program. Those who are familiar with 340B will know that it works by requiring drugmakers to offer discounts on certain outpatient drugs to safety-net hospitals and clinics.
These providers reinvest these savings into providing more care and treating more patients, especially those living with low incomes or in rural areas where care can be scarce. My association represents more than 1,500 hospitals that participate in 340B.
Recently, one of the world’s largest drug companies threatened to upend 340B by fundamentally changing how it has worked for more than 30 years. Johnson & Johnson (J&J) announced it would replace upfront discounts with back-end rebates for two of its top-selling drugs. If allowed to take effect, this would have required certain hospitals to buy those drugs at full cost, send reams of claims data to the drug company, and wait to see when — and if — J&J would pay them the rebates.
It is hard to understate how harmful this would be for 340B hospitals. J&J is not the first drugmaker to propose a rebate system for 340B, but it is the first to threaten to put one in place over a period of a few short weeks and without government approval. Rebate programs force cash-strapped 340B providers to pay significantly higher inventory costs, because they would pay full price for drugs, then wait who knows how longs to receive a 340B rebate, effectively floating massive revenues to profitable drugmakers and going without resources hospitals sorely need to care for vulnerable patients. And it would put the drugmaker — not the federal government — in charge of determining whether the drugs were eligible for 340B under terms that the drugmaker could effectively set itself.
I am glad to report these unlawful 340B rebates will not be taking effect as J&J initially planned. 340B Health and others mobilized advocacy efforts to block these rebates. Nearly 200 members of the U.S House of Representatives signed a bipartisan letter calling on the US Department of Health and Human Services (HHS) secretary to take swift enforcement actions.
HHS directed J&J to cease implementation of its rebate plans or face millions of dollars in fines and even loss of Medicaid and Medicare coverage of all the drugmaker’s products. And in the face of this unified, unwavering, and unequivocal opposition, J&J acknowledged it would back down.
This was a big victory for 340B hospitals, but we must remain vigilant. The debate about replacing 340B discounts with rebates is not new. The pharmaceutical industry has been pushing for rebates for years and shows few signs of relenting on this goal. Even the very strong HHS enforcement response in this instance does not mean drugmakers cannot try proposing a rebate scheme they think might gain federal approval.
The Inflation Reduction Act (IRA) and its upcoming Medicare price caps on top drugs will rely on accurately identifying 340B drugs after they already have been dispensed. J&J argued that turning 340B into a rebate program would help with implementing the IRA. CMS recently clarified that the IRA was not intended to turn 340B into a rebate program.
Manufacturers have other avenues that allow them to comply with both the IRA and 340B. 340B Health will continue to explore all advocacy and legal options to ensure that rebates do not take over 340B.
The support 340B provides to the safety-net and the patients they serve is too important to compromise.
EDITOR’S NOTE:
The opinions expressed in this article are solely those of the author and do not necessarily represent the views or opinions of MedLearn Media. We provide a platform for diverse perspectives, but the content and opinions expressed herein are the author’s own. MedLearn Media does not endorse or guarantee the accuracy of the information presented. Readers are encouraged to critically evaluate the content and conduct their own research. Any actions taken based on this article are at the reader’s own discretion.
A few weeks ago, during the weekly Monitor Monday broadcast, healthcare attorney David Glaser, presented a great segment that simplified the two-midnight rule into two
Imagine the frustration you might feel if, after you negotiate a settlement, under which you are paying a departing employee a respectable sum of money,
Please log in to your account to comment on this article.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 RACmonitor. Powered by MedLearn Media.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
